Literature DB >> 24894397

Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema.

Hidetaka Noma1, Tatsuya Mimura2, Kanako Yasuda1, Masahiko Shimura1.   

Abstract

PURPOSE: To evaluate the association between multiple factors in aqueous humor and the severity of macular edema in patients with branch retinal vein occlusion (BRVO).
METHODS: We measured the aqueous humor levels of 11 factors (including vascular endothelial growth factor receptors, growth factors, and inflammatory factors) in BRVO patients with macular edema and in cataract patients as controls. Aqueous humor samples were obtained from 40 patients (31 patients with BRVO and 9 with cataract). Then the levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR)-1, sVEGFR-2, placental growth factor (PlGF), soluble intercellular adhesion molecule (sICAM)-1, monocyte chemotactic protein (MCP)-1, platelet-derived growth factor (PDGF)-AA, interleukin (IL)-6, IL-8, IL-12(p70), and IL-13 were measured by the suspension array method. Macular edema was examined by optical coherence tomography, and its severity was determined from the central macular thickness (CMT), neurosensory retinal thickness (TNeuro), and subfoveal serous retinal thickness (SRT).
RESULTS: Aqueous humor levels of growth factors, sVEGFR-1, sVEGFR-2, and inflammatory factors were significantly higher in eyes with BRVO than in control eyes. Aqueous levels of sVEGFR-1 and -2 were significantly correlated with the SRT, as well as with the levels of growth factors (PIGF and PDGF-AA) and various inflammatory factors (sICAM-1, MCP-1, IL-6, and IL-8). Levels of the growth factors (VEGF, PlGF, and PDGF-AA) were also significantly correlated with each other.
CONCLUSIONS: These findings suggest the importance of the cytokine network in BRVO patients, and may contribute to understanding the mechanism of macular edema associated with BRVO and to development of new treatments. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  BRVO; PlGF; VEGF; VEGF receptors-1; VEGF receptors-2

Mesh:

Substances:

Year:  2014        PMID: 24894397     DOI: 10.1167/iovs.14-13961

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion.

Authors:  Muge Coban-Karatas; Rana Altan-Yaycioglu; Burak Ulas; Selcuk Sizmaz; Handan Canan; Cagla Sariturk
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study.

Authors:  V Fortoul; P Denis; L Kodjikian
Journal:  Eye (Lond)       Date:  2015-03-20       Impact factor: 3.775

3.  New Drugs and New Posterior Delivery Methods in CME.

Authors:  João Rafael de Oliveira Dias; Renata Portella Nunes; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-04-07

4.  A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.

Authors:  Havva Erdogan Kaldırım; Serpil Yazgan
Journal:  Int Ophthalmol       Date:  2017-06-23       Impact factor: 2.031

5.  Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells.

Authors:  Izuagie Attairu Ikhapoh; Christopher J Pelham; Devendra K Agrawal
Journal:  Differentiation       Date:  2015-04-23       Impact factor: 3.880

6.  EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.

Authors:  Laura Kowalczuk; Alexandre Matet; Ali Dirani; Alejandra Daruich; Aude Ambresin; Irmela Mantel; Richard F Spaide; Natacha Turck; Francine Behar-Cohen
Journal:  Retina       Date:  2017-12       Impact factor: 4.256

7.  Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion.

Authors:  Jing Wang; Ying Li; Shu-Fen Fang; Hong Wang
Journal:  BMC Ophthalmol       Date:  2020-07-09       Impact factor: 2.209

8.  Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration.

Authors:  Ryosuke Motohashi; Hidetaka Noma; Kanako Yasuda; Osamu Kotake; Hiroshi Goto; Masahiko Shimura
Journal:  J Inflamm (Lond)       Date:  2018-12-04       Impact factor: 4.981

9.  Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2.

Authors:  Raja Narayanan; Bhavik Panchal; Michael W Stewart; Taraprasad Das; Jay Chhablani; Subhadra Jalali; Mohd Hasnat Ali
Journal:  Clin Ophthalmol       Date:  2016-06-02

10.  IL-18 and S100A12 Are Upregulated in Experimental Central Retinal Vein Occlusion.

Authors:  Lasse Jørgensen Cehofski; Anders Kruse; Svend Kirkeby; Alexander Nørgård Alsing; Jonas Ellegaard Nielsen; Kentaro Kojima; Bent Honoré; Henrik Vorum
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.